Insulin Manufacturers’, PBMs’ Testimony Regarding Insulin Prices

On Wednesday, April 10, the three manufacturers of insulin in the United States — Eli Lilly, Novo Nordisk and Sanofi — testified before the House Energy and Commerce Oversight Subcommittee regarding their pricing practices. The three largest pharmacy benefit managers (PBMs) also appeared before the committee.

The hearing was the second in two weeks regarding rising insulin prices and how the Congress can make the medicine more affordable. At the first hearing, “Priced Out of a Lifesaving Drug: The Human Impact of Rising Insulin Prices,” officers from the American Diabetes Association, JDRF and other prominent diabetes advocates testified before the committee.

As reported by Healio, Douglas J. Langa, executive vice president of North America operations and president of Novo Nordisk, stated that the insulin manufacturers set the list price of the medicine charged to wholesalers and distributors. He added, however, that the list price is just one factor in a complicated insulin supply chain, including “rebates, discounts and fees paid to PBMs, insurance plans and distributors.”

Insulin Infographic
Courtesy of the American Diabetes Association

Eli Lilly has recently announced plans to introduce a generic version of its rapid-acting insulin Humalog, while Sanofi SA will cut the cost of its insulins to $99 per month for certain patients. Heath insurance company Cigna and PBM Express Scripts have also announced a health insurance plan that will cap insulin costs at $25 monthly.

Read more about the testimony here and watch the proceedings below.

Want to learn how to save money on your insulin? Read “Insulin Prices: Four Ways to Pay Less.”

Learn more about the health and medical experts who who provide you with the cutting-edge resources, tools, news, and more on Diabetes Self-Management.
About Our Experts >>